<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719575</url>
  </required_header>
  <id_info>
    <org_study_id>DA9701_GA_IV</org_study_id>
    <nct_id>NCT01719575</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers</brief_title>
  <acronym>DA-9701</acronym>
  <official_title>A Double-blind, Randomized, Two-way, Cross-over Study for Evaluating Motilitone on Gastric Motor Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of Motilitone and placebo on gastric
      volumes, gastric emptying, small bowel transit and colon transit in female and male healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gastric fuction of Motilitone</measure>
    <time_frame>3 weeks</time_frame>
    <description>gastric emptying time on day 4 by scintigraphic imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gastric function of Motilitone</measure>
    <time_frame>3 weeks</time_frame>
    <description>fasting and postprandial gastric volume on day 7 by single photon emission computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events of Motilitone</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>small bowel function of Motilitone</measure>
    <time_frame>3 weeks</time_frame>
    <description>small bowel transit time on day 4 by scintigraphic transit measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colon function of Motilitone</measure>
    <time_frame>3 weeks</time_frame>
    <description>colon transit time on day 4 and 7 by KUB</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Female and Male</condition>
  <arm_group>
    <arm_group_label>Motilitone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motilitone</intervention_name>
    <arm_group_label>Motilitone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no gastrointestinal symptoms

          -  no organic lesion such as gastrointestinal malignancies, erosive esophagitis, reflux
             esophagitis, erosive gastroduodenitis, gastric or duodenal ulceration after having
             normal upper abdominal endoscopy

          -  written informed consent

        Exclusion Criteria:

          -  pregnant, breast-feeding female,those of childbearing age who were not using an
             approved method of contraception

          -  history of abdominal surgery that may influence gastrointestinal motility

          -  gastrointestinal hemorrhage, mechanical ileus, enterobrosis

          -  irritable bowel syndrome, inflammatory bowel disease

          -  severe disturbance of liver, kidney, heart,lung,blood and endocrine

          -  psychoneurosis, alcoholism, drug dependence

          -  medications that may alter evaluation of Motilitone including
             antibiotics,corticosteroids, NSAID within 1 month, prokinetics, H2 blocker, PPI,
             anticolines, erythromycin, antidepressive agents withing 2weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Gyu Choi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seul St.Mary's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Catholic university of korea college of Medicine, Seoul St.Mary's hospital</name>
      <address>
        <city>Banpo-dong, Seocho-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

